Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05602194CT.gov Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05292664CT.gov Venetoclax Basket Trial for High Risk Hematologic Malignancies | — | Recruiting | — | — | — |
NCT03117751CT.gov Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoblastic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Calaspargase Pegol (this asset) | Children's Oncology Group | P3 | BB · 70 |
| Cladribine | Fifth Affiliated Hospital, Sun Yat-Sen University | P4 | BBB |
| Rituximab | University of Washington | P4 | BBB |
| Mercaptopurine Anhydrous | City of Hope Medical Center | P4 | BBB |
| Etoposide | University of Washington | P4 | BBB |
| Vindesine | University Hospital Muenster | P4 | BBB |
| Pegaspargase | Chongqing Peg-Bio Biopharm Co., Ltd. | P4 | BBB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Methotrexate | City of Hope Medical Center | P4 | BB |
+42 more in the Lymphoblastic Lymphoma cohort
Other indications for Calaspargase Pegol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| B-Cell Adult Acute Lymphocytic Leukemia | — | P3 | BB · 64 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Calaspargase Pegol in Lymphoblastic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/calaspargase-pegol-lymphoblastic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →